AbbVie announced positive Phase 3 results for etentamig, a BCMA x CD3 bispecific T-cell engager, in treating triple-class exposed relapsed/refractory multiple myeloma. The CERVINO study showed etentamig achieved a 74% objective response rate and a 60% reduction in disease progression risk compared to standard therapies. It also demonstrated a manageable safety profile with low rates of severe cytokine release syndrome and infections, supporting its potential for outpatient and community care use. AbbVie plans to discuss these results with regulators to determine next steps for approval and broader patient access.
AbbVie confirmed its $11 billion acquisition of Apogee Therapeutics, enhancing its drug pipeline in immunology, oncology, neuroscience, and aesthetics. The deal causes only modest near-term earnings dilution. AbbVie's Q2 results beat expectations, dr...
AbbVie has finalized its $10.9 billion acquisition of Apogee Therapeutics, enhancing its immunology portfolio with Apogee's late-stage drug candidates targeting inflammatory diseases like atopic dermatitis and asthma. Apogee's lead asset, zumilokibar...
AbbVie announced it will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026. The company's management will engage in a fireside chat at 9:00 a.m. Central time, which will be accessible via a live audio we...
JPMorgan's JEPI ETF offers an 8.33% yield mainly from option premiums and large-cap stocks, but in taxable accounts, most distributions are taxed as ordinary income, not at the lower qualified dividend rate. This results in a significant tax penalty—...
Allergan Aesthetics, part of AbbVie, introduced two new skincare products under the SkinMedica brand: Barrier Calming Cream and HA 5 Hydra Collagen Facial Mist. The Barrier Calming Cream, featuring Calcium Strengthening and Botanical Calming Complexe...
